IVVD

Invivyd

0.73

0.04+5.52%

After Hours: 0.7399 +0.0076 +1.04%19:32 08/01 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.7020/0.6940

TODAY RANGE0.6900-0.7388

VOL824.00K

MARKET CAP87.85M

52 WEEK RANGE0.3546-2.740

AVG VOL (3M)1.74M

% TURNOVER0.69%

TURNOVER--

P/E (TTM)-0.6133

% RANGE7.03%

EPS(TTM)-1.1940

P/E(FORWARD)-6.1025

P/B1.622

BVPS0.4514

DIVIDEND--

P/S3.458

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP50.99M

SHARES OUTSTANDING119.96M

NEXT EARNINGS08/06-08/11

FREE FLOAT69.63M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·07/23 11:10
Invivyd announces addition of Iwasaki to SPEAR Study Group
Barchart·07/23 06:01
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
Benzinga·07/21 11:13
Invivyd Says Updated National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology For Cancer-related Infections Now Recommend The Use Of Available Monoclonal Antibodies For Pre-exposure Prophylaxis Of Covid-19
Benzinga·07/21 11:11
Invivyd Says Updated NCCN Guidelines For Prevention And Treatment Of Cancer-Related Infections Now Recommend Use Of Available Monoclonal Antibodies For Pre-Exposure Prophylaxis Of COVID-19
TipRanks·07/21 11:10
Invivyd announces updated NCCN Clinical Practice Guidelines for COVID-19
Barchart·07/21 06:05
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
Benzinga·07/02 11:11
Invivyd Launches SPEAR Study Group to Explore Monoclonal Antibody Treatment for Long COVID and Post-Vaccine Syndrome
TipRanks·07/02 11:10
Invivyd forms SPEAR study group to assess therapy for long-COVID
Dow Jones·06/26 16:24
Invivyd Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Benzinga·06/26 16:14
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $5 Price Target
TipRanks·06/26 14:35
Invivyd’s VYD2311: Promising Phase 1/2 Trial Results and Strategic Positioning Support Buy Rating
Dow Jones·06/26 12:25
Invivyd Is Maintained at Buy by D. Boral Capital
NASDAQ·06/26 11:11
Invivyd, Inc. Announces Promising Phase 1/2 Data for VYD2311 Monoclonal Antibody Candidate in COVID-19 Prevention and Treatment
TipRanks·06/26 11:05
Invivyd announces full Phase 1/2 clinical data for VYD2311
Benzinga·06/26 11:04
Invivyd Announces Full Phase 1/2 Clinical Data For VYD2311, Next-Gen Monoclonal Antibody Candidate Designed To Prevent And Treat COVID-19

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

+0.76%

698.80

Biogen Inc

BIIB

+3.09%

131.95

Amgen Inc

AMGN

+0.60%

296.88

Shire

SHPG

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

0.00%

0.0301

Lilly Eli & Co

LLY

+3.01%

762.33

Celgene

CELG

108.24

Therapeuticsmd Inc

TXMD

-0.89%

1.11

Johnson & Johnson

JNJ

+1.57%

167.33

Abbvie Inc

ABBV

+3.28%

195.22

Zoetis Inc

ZTS

+1.09%

147.38

Gilead Sciences Inc

GILD

+0.79%

113.18

Novo-Nordisk A/S

NVO

+2.38%

48.19

Bristol-Myers Squibb Co

BMY

+2.12%

44.23

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+0.86%

23.49

Sanofi FR

SNY

+2.43%

46.75

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+1.37%

115.30

Dr Reddys Labs

RDY

-1.97%

13.94

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English